[
  {
    "title": "QQQ ETF Update, 4/15/2024\ufffd\ufffd\ufffd",
    "published": 1713159000,
    "posting_price": 198.72999573,
    "close_price": 196.80000305,
    "percent_change": -0.97116325
  },
  {
    "title": "Biogen Is Suffering From Doubts About the Future",
    "published": 1712930402,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "GLP-1s benefit Parkinson\u2019s: Barclays sees implications across biopharma",
    "published": 1712919780,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "ClearBridge Aggressive Growth Strategy Q1 2024 Portfolio Manager Commentary",
    "published": 1712906400,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "Biogen price target lowered by $20 at BofA, here's why",
    "published": 1712901420,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map",
    "published": 1712898708,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "SPY ETF Update, 4/12/2024",
    "published": 1712896500,
    "posting_price": 204.22999573,
    "close_price": 198.17999268,
    "percent_change": -2.96234793
  },
  {
    "title": "Where Biogen Stands With Analysts",
    "published": 1712837160,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "BIIB May 31st Options Begin Trading",
    "published": 1712831760,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "Alkermes' Innovations Are Transforming Mental Health Treatments",
    "published": 1712822460,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "QQQ ETF Update, 4/11/2024",
    "published": 1712816580,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "Biogen price target lowered by $30 at JPMorgan, here's why",
    "published": 1712811720,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)",
    "published": 1712811660,
    "posting_price": 202.75999451,
    "close_price": 203.67999268,
    "percent_change": 0.45373752
  },
  {
    "title": "ClearBridge Value Equity Strategy Q1 2024 Portfolio Manager Commentary",
    "published": 1712753400,
    "posting_price": 203.0,
    "close_price": 201.55000305,
    "percent_change": -0.71428421
  },
  {
    "title": "SPY ETF Update, 4/10/2024",
    "published": 1712727420,
    "posting_price": 203.0,
    "close_price": 201.55000305,
    "percent_change": -0.71428421
  },
  {
    "title": "10 Health Care Stocks With Whale Alerts In Today's Session",
    "published": 1712666400,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)",
    "published": 1712640660,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "QQQ ETF Update, 4/9/2024",
    "published": 1712639520,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "Biogen Inc. stock outperforms competitors on strong trading day",
    "published": 1712635440,
    "posting_price": 205.02000427,
    "close_price": 206.52000427,
    "percent_change": 0.73163592
  },
  {
    "title": "Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",
    "published": 1712473500,
    "posting_price": 203.88999939,
    "close_price": 204.94999695,
    "percent_change": 0.51988698
  },
  {
    "title": "BIIB May 24th Options Begin Trading",
    "published": 1712224920,
    "posting_price": 207.24000549,
    "close_price": 205.30000305,
    "percent_change": -0.93611387
  },
  {
    "title": "SPY ETF Update, 4/4/2024\ufffd\ufffd\ufffd",
    "published": 1712194620,
    "posting_price": 207.24000549,
    "close_price": 205.30000305,
    "percent_change": -0.93611387
  },
  {
    "title": "QQQ ETF Update, 4/3/2024",
    "published": 1712123160,
    "posting_price": 207.71000671,
    "close_price": 206.38000488,
    "percent_change": -0.64031669
  },
  {
    "title": "Biogen price target lowered by $15 at Barclays, here's why",
    "published": 1712119200,
    "posting_price": 207.71000671,
    "close_price": 206.38000488,
    "percent_change": -0.64031669
  },
  {
    "title": "Looking Into Biogen's Recent Short Interest",
    "published": 1712112480,
    "posting_price": 207.71000671,
    "close_price": 206.38000488,
    "percent_change": -0.64031669
  },
  {
    "title": "Biotech Roundtable: Who will bring the next CRISPR drug to market?",
    "published": 1712054340,
    "posting_price": 213.08999634,
    "close_price": 207.63999939,
    "percent_change": -2.55760338
  },
  {
    "title": "Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings",
    "published": 1714484400,
    "posting_price": 214.66000366,
    "close_price": 214.82000732,
    "percent_change": 0.07453818
  },
  {
    "title": "Biogen: Don't Overthink This One",
    "published": 1714481224,
    "posting_price": 214.66000366,
    "close_price": 214.82000732,
    "percent_change": 0.07453818
  },
  {
    "title": "How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?",
    "published": 1714424427,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "7 Retirement Stocks to Buy at a 52-Week Low in April",
    "published": 1714399393,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "10 Most Promising Stocks to Buy Before They Take Off",
    "published": 1714398604,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week",
    "published": 1714395360,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "The Analyst Landscape: 27 Takes On Biogen",
    "published": 1714392300,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors Limiting Growth",
    "published": 1714385040,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Biogen (BIIB)'s Market Evaluation: A Fair Valuation Analysis",
    "published": 1714383120,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)",
    "published": 1714381200,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Oppenheimer Remains a Buy on Biogen (BIIB)",
    "published": 1714373940,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag",
    "published": 1714310770,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think",
    "published": 1714222596,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "ClearBridge All Cap Growth Strategy Q1 2024 Commentary",
    "published": 1714212000,
    "posting_price": 208.99000549,
    "close_price": 215.5,
    "percent_change": 3.11497887
  },
  {
    "title": "Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates",
    "published": 1714145220,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "Biogen\u2019s Financial Upswing: Strong Q1 Performance and Market Penetration Justify Buy Rating",
    "published": 1714136340,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals",
    "published": 1714134300,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "BIIB June 7th Options Begin Trading",
    "published": 1714129920,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "Sage Therapeutics price target lowered by $11 at RBC Capital, here's why",
    "published": 1714114740,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "Decoding Biogen Inc (BIIB): A Strategic SWOT Insight",
    "published": 1714107766,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)",
    "published": 1714107060,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "Buy Rating Justified: Biogen\u2019s Promising Drug Launches and Strategic Growth Initiatives",
    "published": 1714094580,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "Biogen\u2019s Surpassing Performance and Positive Outlook Affirm Buy Rating",
    "published": 1714093800,
    "posting_price": 201.22000122,
    "close_price": 208.8999939,
    "percent_change": 3.81671436
  },
  {
    "title": "Biogen Receives Positive CHMP Opinion for TOFIDENCE\u2122 (tocilizumab), a Biosimilar Referencing ROACTEMRA\u00ae",
    "published": 1714075500,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX",
    "published": 1714069680,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript",
    "published": 1714068946,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year",
    "published": 1714056727,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "For Beaten-Down Maker of Alzheimer\u2019s Drug, Good Enough Will Do",
    "published": 1714042800,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "These Analysts Revise Their Forecasts On Biogen After Q1 Results",
    "published": 1714031640,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday",
    "published": 1714031220,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen price target raised by $2 at Wedbush, here's why",
    "published": 1714030140,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "GLOBAL BROKER RATINGS: Bank of America raises Tesla to 'buy'",
    "published": 1714029060,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Jefferies Keeps Their Buy Rating on Biogen (BIIB)",
    "published": 1714028220,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Analysts\u2019 Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Universal Health (UHS)",
    "published": 1714026780,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen price target lowered by $10 at BofA, here's why",
    "published": 1714026540,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen price target lowered by $25 at H.C. Wainwright, here's why",
    "published": 1714026360,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB)",
    "published": 1714025460,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)",
    "published": 1714024980,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen price target raised by $3 at Canaccord, here's why",
    "published": 1714024740,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Q1 2024 Biogen Inc Earnings Call",
    "published": 1714022582,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Biogen (BIIB) and Molina Healthcare (MOH)",
    "published": 1714020060,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen price target lowered by $15 at Barclays, here's why",
    "published": 1714017540,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen announces CHMP opinion recommending Tofidence",
    "published": 1714016760,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen receives positive CHMP opinion for TOFIDENCE",
    "published": 1714016700,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Sage Therapeutics price target lowered by $4 at Truist, here's why",
    "published": 1714007760,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Biogen Inc (BIIB) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...",
    "published": 1714007160,
    "posting_price": 201.21000671,
    "close_price": 202.46000671,
    "percent_change": 0.62124147
  },
  {
    "title": "Why Biogen Stock Leaped Nearly 5% Higher Today",
    "published": 1713997092,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Stock Surges After Two Notable Products Walloped Sales Expectations",
    "published": 1713989997,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings",
    "published": 1713982372,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake",
    "published": 1713977820,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen (BIIB) Q1 2024 Earnings Call Transcript",
    "published": 1713977115,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen: Don\u2019t expect any big acquisitions this year",
    "published": 1713976080,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "NEW YORK MARKET CLOSE: Stocks ease off the throttle but Tesla motors",
    "published": 1713975240,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer\u2019s Drug",
    "published": 1713971280,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen stock rises on Q1 results, Alzheimer's drug sales",
    "published": 1713968933,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Affirms Guidance After Mixed First Quarter",
    "published": 1713967547,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Alzheimer\u2019s Drug Leqembi Sees Sales Pickup, Boosting Biogen Stock",
    "published": 1713965946,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Beats Estimates as Alzheimer\u2019s Drug Gains Traction",
    "published": 1713965687,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "published": 1713965430,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?",
    "published": 1713962700,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts",
    "published": 1713961932,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen sees \u2018encouraging\u2019 trends for postpartum depression drug",
    "published": 1713960960,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen to invest more in launch of Alzheimer\u2019s drug Leqembi",
    "published": 1713960540,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "What You Missed On Wall Street This Morning",
    "published": 1713960240,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript",
    "published": 1713957925,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024",
    "published": 1713956220,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow start",
    "published": 1713955715,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen beats quarterly profit estimates, Alzheimer's drug sales jump",
    "published": 1713955500,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen confident in annual outlook despite drop in quarterly revenue",
    "published": 1713948540,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Boston Scientific (BSX) and Biogen (BIIB)",
    "published": 1713946320,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Fly Intel: Pre-market Movers",
    "published": 1713945060,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen: 8% increase in quarterly EPS",
    "published": 1713944710,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen\u2019s stock climbs as first-quarter profit tops estimates, Alzheimer\u2019s drug uptake improves",
    "published": 1713944460,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen says uptake for Alzheimer\u2019s therapy is improving",
    "published": 1713942300,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and BioMarin Pharmaceutical (BMRN)",
    "published": 1713942060,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen first-quarter profit tops estimates as Alzheimer\u2019s drug uptake improves",
    "published": 1713938400,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Non-GAAP EPS of $3.67 beats by $0.21, revenue of $2.29B misses by $30M",
    "published": 1713938220,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen backs FY24 adjusted EPS view of $15.00-$16.00, consensus $15.46",
    "published": 1713937800,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen reports Q1 adjusted EPS $3.67, consensus $3.44",
    "published": 1713937740,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally",
    "published": 1713937140,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)",
    "published": 1713933780,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "QQQ ETF Update, 4/24/2024",
    "published": 1713932940,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Biogen Inc. stock outperforms competitors on strong trading day",
    "published": 1713931560,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "What You Missed On Wall Street On Wednesday",
    "published": 1713928440,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Notable Wednesday Option Activity: BIIB, ABNB, HPQ",
    "published": 1713920400,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "GLOBAL BRIEFING: Stocks called higher; Australia's inflation edges up",
    "published": 1713919200,
    "posting_price": 198.97000122,
    "close_price": 201.99000549,
    "percent_change": 1.51781889
  },
  {
    "title": "Notable companies reporting before tomorrow's open",
    "published": 1713874680,
    "posting_price": 193.33999634,
    "close_price": 193.17999268,
    "percent_change": -0.08275766
  },
  {
    "title": "Biogen Q1 2024 Earnings Preview",
    "published": 1713866820,
    "posting_price": 193.33999634,
    "close_price": 193.17999268,
    "percent_change": -0.08275766
  },
  {
    "title": "Notable earnings before Wednesday's open",
    "published": 1713864720,
    "posting_price": 193.33999634,
    "close_price": 193.17999268,
    "percent_change": -0.08275766
  },
  {
    "title": "Morning Brew: Tech Giants Lead Market Movements Amid Earnings Releases",
    "published": 1713857460,
    "posting_price": 193.33999634,
    "close_price": 193.17999268,
    "percent_change": -0.08275766
  },
  {
    "title": "Should You Be Confident in Biogen (BIIB)?",
    "published": 1713846234,
    "posting_price": 193.33999634,
    "close_price": 193.17999268,
    "percent_change": -0.08275766
  },
  {
    "title": "QQQ ETF Update, 4/23/2024",
    "published": 1713846000,
    "posting_price": 193.33999634,
    "close_price": 193.17999268,
    "percent_change": -0.08275766
  },
  {
    "title": "Eli Lilly And The Alzheimer's Dilemma (Rating Upgrade)",
    "published": 1713787200,
    "posting_price": 196.19000244,
    "close_price": 194.11000061,
    "percent_change": -1.06019767
  },
  {
    "title": "Piper Sandler Sticks to Its Buy Rating for Biogen (BIIB)",
    "published": 1713770940,
    "posting_price": 196.19000244,
    "close_price": 194.11000061,
    "percent_change": -1.06019767
  },
  {
    "title": "Top high growth investment ratio stocks from each sector - GS",
    "published": 1713756360,
    "posting_price": 196.19000244,
    "close_price": 194.11000061,
    "percent_change": -1.06019767
  },
  {
    "title": "Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",
    "published": 1713683100,
    "posting_price": 196.19000244,
    "close_price": 194.11000061,
    "percent_change": -1.06019767
  },
  {
    "title": "Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week",
    "published": 1713674940,
    "posting_price": 196.19000244,
    "close_price": 194.11000061,
    "percent_change": -1.06019767
  },
  {
    "title": "What's in Store for Biogen (BIIB) This Earnings Season?",
    "published": 1713533940,
    "posting_price": 190.72000122,
    "close_price": 194.38000488,
    "percent_change": 1.91904553
  },
  {
    "title": "Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics",
    "published": 1713532524,
    "posting_price": 190.72000122,
    "close_price": 194.38000488,
    "percent_change": 1.91904553
  },
  {
    "title": "Top 10 most oversold S&P 500 stocks",
    "published": 1713524580,
    "posting_price": 190.72000122,
    "close_price": 194.38000488,
    "percent_change": 1.91904553
  },
  {
    "title": "Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)",
    "published": 1713509460,
    "posting_price": 190.72000122,
    "close_price": 194.38000488,
    "percent_change": 1.91904553
  },
  {
    "title": "Biogen price target lowered by $20 at Oppenheimer, here's why",
    "published": 1713509040,
    "posting_price": 190.72000122,
    "close_price": 194.38000488,
    "percent_change": 1.91904553
  },
  {
    "title": "Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for",
    "published": 1713448899,
    "posting_price": 191.75,
    "close_price": 190.52000427,
    "percent_change": -0.64145801
  },
  {
    "title": "Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth",
    "published": 1713362482,
    "posting_price": 196.36000061,
    "close_price": 192.16000366,
    "percent_change": -2.13892694
  },
  {
    "title": "Global company events calendar",
    "published": 1713344220,
    "posting_price": 196.36000061,
    "close_price": 192.16000366,
    "percent_change": -2.13892694
  },
  {
    "title": "ClearBridge Multi Cap Growth Strategy Q1 2024 Portfolio Manager Commentary",
    "published": 1713340800,
    "posting_price": 196.36000061,
    "close_price": 192.16000366,
    "percent_change": -2.13892694
  },
  {
    "title": "QQQ ETF Update, 4/17/2024",
    "published": 1713333180,
    "posting_price": 196.36000061,
    "close_price": 192.16000366,
    "percent_change": -2.13892694
  },
  {
    "title": "As more rare disease therapies launch, their prices are rising",
    "published": 1713266880,
    "posting_price": 196.19999695,
    "close_price": 195.1499939,
    "percent_change": -0.53516976
  },
  {
    "title": "Biogen\u2019s Alzheimer's drug to cost $3.5B for Medicare in 2025: report",
    "published": 1713234720,
    "posting_price": 196.19999695,
    "close_price": 195.1499939,
    "percent_change": -0.53516976
  }
]